Quince Therapeutics, Inc. (QNCX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -127.16M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 32.99M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-127.16M | (m) | (m) | $32.99M | (m) | (m) |
| 2026-03-31 | $-57.80M | (m) | (m) | $34.08M | (m) | (m) |
| 2025-12-31 | $-58.07M | (m) | (m) | $35.38M | (m) | (m) |
| 2025-09-30 | $-50.73M | (m) | (m) | $28.61M | (m) | (m) |
| 2025-06-30 | $-43.16M | (m) | (m) | $25.44M | (m) | (m) |
| 2025-03-31 | $-60.92M | (m) | (m) | $23.03M | (m) | (m) |
| 2024-12-31 | $-57.28M | (m) | (m) | $18.59M | (m) | (m) |
| 2024-09-30 | $-55.19M | (m) | (m) | $16.20M | (m) | (m) |
| 2024-06-30 | $-55.49M | (m) | (m) | $12.71M | (m) | (m) |
| 2024-03-31 | $-32.88M | (m) | (m) | $9.92M | (m) | (m) |
| 2023-12-31 | $-34.62M | (m) | (m) | $9.45M | (m) | (m) |
| 2023-09-30 | $-31.02M | (m) | (m) | $8.78M | (m) | (m) |
| 2023-06-30 | $-32.48M | (m) | (m) | $9.80M | (m) | (m) |
| 2023-03-31 | $-43.11M | (m) | (m) | $15.65M | (m) | (m) |
| 2022-12-31 | $-52.02M | (m) | (m) | $25.18M | (m) | (m) |
| 2022-09-30 | $-69.24M | (m) | (m) | $37.62M | (m) | (m) |
| 2022-06-30 | $-83.30M | (m) | (m) | $49.21M | (m) | (m) |
| 2022-03-31 | $-88.87M | (m) | (m) | $56.73M | (m) | (m) |
| 2021-12-31 | $-90.32M | (m) | (m) | $60.80M | (m) | (m) |
| 2021-09-30 | $-87.63M | (m) | (m) | $61.44M | (m) | (m) |
| 2021-06-30 | $-87.86M | (m) | (m) | $64.38M | (m) | (m) |
| 2021-03-31 | $-84.35M | (m) | (m) | $63.75M | (m) | (m) |
| 2020-12-31 | $-78.89M | (m) | (m) | $61.31M | (m) | (m) |
| 2020-09-30 | $-70.99M | (m) | (m) | $55.48M | (m) | (m) |
| 2020-06-30 | $-59.65M | (m) | (m) | $46.75M | (m) | (m) |
| 2020-03-31 | $-50.95M | (m) | (m) | $39.77M | (m) | (m) |
| 2019-12-31 | $-39.17M | (m) | (m) | $30.21M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-12.12M | (m) | (m) | $10.09M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |